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Abstract
Purpose The potential of renal MRI biomarkers has been increasingly recognised, but clinical translation requires more 
standardisation. The PARENCHIMA consensus project aims to develop and apply a process for generating technical recom-
mendations on renal MRI.
Methods A task force was formed in July 2018 focused on five methods. A draft process for attaining consensus was dis-
tributed publicly for consultation and finalised at an open meeting (Prague, October 2018). Four expert panels completed 
surveys between October 2018 and March 2019, discussed results and refined the surveys at a face-to-face meeting (Aarhus, 
March 2019) and completed a second round (May 2019).
Results A seven-stage process was defined: (1) formation of expert panels; (2) definition of the context of use; (3) literature 
review; (4) collection and comparison of MRI protocols; (5) consensus generation by an approximate Delphi method; (6) 
reporting of results in vendor-neutral and vendor-specific terms; (7) ongoing review and updating. Application of the process 
resulted in 166 consensus statements.
Conclusion The process generated meaningful technical recommendations across very different MRI methods, while allow-
ing for improvement and refinement as open issues are resolved. The results are likely to be widely supported by the renal 
MRI community and thereby promote more harmonisation.
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Introduction
The past few years have seen a surge in the interest in func-
tional and quantitative magnetic resonance imaging (MRI) 
of the kidney (Fig. 1). In October 2015, the first international 
meeting on renal MRI was organised in Bordeaux [1], fol-
lowed in 2017 by the second meeting in Berlin [2], and a 
third meeting in October 2019 in Nottingham, UK [3]. In 
2016, a pan-European network of researchers in renal MRI 
(PARENCHIMA) was funded for 4 years by the European 
Cooperation in Science and Technology (COST) [4]. In 
the UK, a Renal Imaging Network (UKRIN) was set up in 
2016 in collaboration with the charity Kidney Research UK 
[5], and in 2018 was awarded a Medical Research Council 
(MRC) Partnership grant to develop a national infrastruc-
ture for clinical renal MRI research [6]. Also in 2018, the 
National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) at the National Institutes of Health in 
the USA conducted a workshop on renal imaging as a criti-
cal review for current state-of-the-art and to plan potential 
future endeavours [7].
The interest in renal MRI is strongly driven by clinical 
demand, as evidenced by the leading role of nephrologists 
and radiologists in developing networks and the increasing 
exposure of renal MRI in the clinical literature. In 2018, 
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the leading European nephrology journal Nephrology Dialy-
sis Transplantation published a special issue on renal MRI 
[8], with a clinical position statement supported by over 30 
authors including leading European nephrologists [9]. The 
authors emphasise that renal diseases pose a significant and 
escalating socioeconomic burden on health-care systems 
worldwide, and that the development of better diagnos-
tics and prognostics is well recognised as a key strategy to 
address these challenges. MRI biomarkers show promise in 
that respect due to their non-invasive nature and potential for 
early detection of parenchymal changes caused by disease 
progression or treatment effects.
A key challenge in clinical translation of MRI biomarkers 
is the need to build strong evidence of their clinical utility 
on a scale and with a level of rigour that would satisfy the 
expectations of regulators. This is particularly challenging in 
chronic kidney disease (CKD) where very large and/or very 
lengthy studies are required to collect sufficient outcome 
data. The magnitude of this challenge is illustrated by the 
qualification by the Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) of total kidney 
volume as a prognostic enrichment biomarker for autosomal 
dominant polycystic kidney disease (ADPKD)—one of only 
a handful of clinical biomarkers approved by FDA and the 
only imaging biomarker so far [10]. The qualification was 
the end result of a process that lasted over a decade and was 
only possible after a coordinated effort of the entire ADPKD 
community in harmonising and combining data from various 
sources. All other renal MRI biomarkers are at the start of 
that trajectory [11–14]. Evidence of clinical utility is emerg-
ing from small studies, but there is a clear need for larger 
multi-centre studies.
The first step in scaling up the evidence level is the crea-
tion of a more harmonised and standardised approach to data 
collection. Indeed, MRI sequences are complex and depend 
on many parameters that must be optimised and fine-tuned 
separately. Similarly, a wide range of simplifying assump-
tions can and must be made to arrive at well-determined 
models during the analysis phase. Currently different groups 
make different choices of MRI pulse sequences and data 
analysis steps, and therefore the data are not necessarily 
directly comparable. Moreover, calibration and quality con-
trol of MRI equipment and the resulting measurements are 
not common practice and not mandatory, unlike imaging 
modalities that use ionising radiation. The lack of readily 
available and generally accepted protocols also creates bar-
riers for new groups and clinical sites, often requiring exten-
sive and costly in-house optimisation.
In May 2018, a drive towards standardisation in renal 
MRI was initiated by the task force on Technical Recom-
mendations for Clinical Renal MRI, of the COST Action 
PARENCHIMA [4]. The specific aims of the task force 
were to (1) develop a process for generating technical rec-
ommendations across different renal MRI modalities, and (2) 
apply this in areas of key current interest. For this first stage, 
it was decided to focus on five classes of renal MRI tech-
niques that were prioritised by the clinical working group in 
PARENCHIMA [11–14]: renal T1 and T2 mapping, arterial 
spin labelling (ASL), diffusion-weighted imaging (DWI) 
and blood oxygenation level-dependent MRI (BOLD). Com-
bined, they assured a broad coverage of potential biomarkers 
with very different pathophysiological origins to test and 
refine the process before rolling it out more widely across 
renal MRI methods.
We report in this paper how the process for generating 
technical recommendations was developed (methods) and 
describe the process itself in detail (results). The specific 
technical recommendations for these four renal MRI tech-
niques are reported in four separate publications (submitted).
Methods
As a basis for discussion, the task force lead (S.S.) drafted 
a framework and process for development of the techni-
cal recommendations throughout May and June 2018. The 
Fig. 1  Evolution in the cumulative number of publications in the 
context of renal imaging for each class of techniques for which rec-
ommendations were developed. Data were retrieved from mul-
tiple (n = 124) PubMed searches using the string: (kidney* OR 
renal) AND < TECHNIQUE > AND MRI AND < year > [PDAT], 
where < TECHNIQUE > is one of the following substrings: (diffu-
sion-weighted imaging OR diffusion tensor imaging OR intravoxel 
incoherent motion), arterial spin label*, blood oxygenation-level 
dependent and (T1 mapping OR T2 mapping), respectively, for the 
techniques: diffusion imaging, arterial spin labelling, BOLD and 
 T1&T2 mapping and < year > varied from 1989 to 2019 with incre-
ments of 1 (only the last 15 years shown). Duplicates were removed. 
This plot is meant to capture the overall trend over time rather than 
accurate numbers of publications and the search could be refined by 
including for instance abbreviated names of techniques, followed by 
manual removal of search results that are out of scope
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draft was placed on the public task force website [15] for 
consultation until the date of the PARENCHIMA plenary 
meeting in Prague (Czech Republic, October 4th 2018). 
Feedback was invited by June 24 via the PARENCHIMA 
mailing list including over 200 experts in renal MRI.
At the same time, four expert panels were created to 
develop the recommendations for renal T1 and T2 mapping, 
ASL, DWI and BOLD methods. Invitations to join those 
panels were made to the authors of review papers [11–13] 
and also through an open invite via the PARENCHIMA 
online community. A call for experts was also made at the 
NIDDK renal imaging workshop in July 2018, and corre-
sponding authors from recent publications were contacted 
individually. All invitations to join the panels included 
specific requests to feed back on the online draft process. 
After the panels were populated, the task force lead invited 
one senior member to act as chair, who then identified a 
junior co-chair.
As a publication route for the recommendations and the 
process itself, the task force proposed a special issue on 
renal MRI biomarkers to the journal Magnetic Resonance 
Materials in Physics, Biology, and Medicine (MAGMA). 
The proposal was accepted by the editorial board in Sep-
tember 2018 with a deadline of July 1 2019 for the submis-
sion of recommendations.
The draft process was discussed, finalised and agreed 
upon during the public plenary PARENCHIMA meeting in 
Prague (October 4 and 5, 2018) during two dedicated 2-h 
sessions (attendance around 50). The discussion included 
a review of the draft process and feedback, a presentation 
by one of the authors of the successful recommendations 
initiative for ASL in the brain [16], progress reports of 
the four expert panels, and a group discussion on the draft 
process. After the meeting, the online draft process was 
updated to reflect the decisions made in Prague and circu-
lated on October 7, 2018 to all members of the expert pan-
els for final feedback and approval by October 13, 2018.
The agreed process included consensus formation by 
a Delphi method [17], which involved iterative data col-
lection through surveys. The four expert panels started 
the implementation on October 13, 2018 and completed 
a first round of surveys before March 2019. On March 18 
and 19, 2019 an intermediate meeting was organised in 
Aarhus (Denmark) including the task force lead and four 
to five representatives from each panel [18]. The aim of the 
meeting was: (1) to evaluate and interpret the results from 
the first survey and plan the next iteration; (2) to identify 
discrepancies and overlaps between panels and harmonise 
the process going forward. After the Aarhus meeting, a 
final round of surveys was performed, from both the origi-
nal respondents and additional invitees identified in the 
literature and within PARENCHIMA.
An ad hoc meeting with the task force lead, the panel 
chairs, co-chairs and available participants of the panels 
was organised during the ISMRM (International Society 
of Magnetic Resonance in Medicine) in May 2019 (Mon-
treal, Canada). At this meeting it was agreed that response 
numbers and levels of agreement were adequate and it was 
decided to close the surveys for further submissions. The 
final reports of the process itself (this paper) and all four 
technical recommendations were written up independently, 
and subsequently edited for formatting and presentation as 
a coherent set of results. After approval by all authors, the 
wording of the process on the task force website [15] was 
replaced by a link to a preprint of this paper. A GitHub page 
was created as a placeholder for future submissions of com-
pliant MRI protocols and released on Zenodo [19].
Results
We report here the process for developing technical recom-
mendations in clinical MRI agreed upon by PARENCHIMA. 
This includes a specific aim and three long-term objectives, 
four guiding principles and an explicit seven-stage process.
The specific aim of the PARENCHIMA consensus pro-
cess was defined as “the development and maintenance of 
technical recommendations on the measurement of clinical 
renal MRI biomarkers that are widely accepted by a broad 
body of experts in the field”. Three broader, more long-term 
objectives were defined, underlining the understanding that 
standardisation of current methods and innovative design 
of their next iteration are both crucial endeavours to clinical 
and scientific progress:
1. To promote a more standardised approach to renal MRI 
biomarker acquisition. This will facilitate direct com-
parison of quantitative measures by different groups 
and the evaluation of new technical developments. In 
addition, this can lead to subsequent clinical trials with 
nearly identical outcome measures, enabling a rapid 
establishment of Cochrane type of reviews to change 
clinical practice.
2. To improve the efficacy of research in renal MRI bio-
markers and grow the field by providing a recommended 
list of parameters to guide the setup of protocols. This 
will significantly reduce the barriers for setting up new 
clinical studies, especially when they involve multiple 
sites and/or vendors.
3. To identify priorities for future research and develop-
ment by highlighting aspects of quantitative MRI meth-
ods where no recommendation is currently possible. 
These most likely relate to advanced contrast features 
that are yet to be definitively understood and should 
remain an active area of innovation and research.
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Four general principles were defined to guide the devel-
opment of the recommendations:
1. Promoting uptake Recommendations should be put 
forward in consensus by a representative expert panel 
of scientists, using a Delphi method to avoid a bias 
caused by peer pressure. This will ensure that they are 
widely supported and maximise their global uptake in 
future studies. Every effort should be made to invite and 
include all experts currently active in the relevant field 
and ensure the panel covers expertise with hardware and 
software from multiple MRI vendors.
2. Building on expertise Ideally, the recommendations 
should be based on hard scientific evidence that identi-
fies the “best” measurement approach for any specific 
MRI biomarker. In practice, the evidence will often be 
insufficient, and in that case the recommendations can be 
based on the personal expertise of the panel members. 
In cases where a consensus cannot be reached, the panel 
can instead flag the issue as a priority for future research 
and development.
3. Promoting innovation The technology of MRI is rap-
idly evolving and new insights and data are emerging 
on a regular basis. Recommendations should not act as 
a brake on innovation, but rather promote it by offering 
a well-accepted benchmark for new developments. Rec-
ommendations should be version controlled and revis-
ited by the panel at regular intervals, or ad hoc when 
new evidence and technology become available.
4. Serving the context of use The optimal approach may 
depend on the clinical application (e.g. native vs. trans-
planted kidneys, children vs. adults) and may also be 
biomarker specific (e.g. fractional anisotropy vs. appar-
ent diffusion coefficient). Other constraints may exist, 
such as maximum duration or cost of the scan. Where 
appropriate, panels should therefore consider dedicated 
recommendations for individual clinical application 
areas.
A seven-stage process was defined to develop the recom-
mendations, covering the full life cycle from convening the 
panel to long-term maintenance:
Stage 1. Composition of the panels Convene a panel 
of experts that is representative of the field, including 
experts from across the world and ideally covering exper-
tise with all major vendors. Identify a senior chair and a 
junior co-chair to lead the panel. Their role is to ensure 
the membership of the panel is representative of the field, 
coordinate the development of the recommendations, 
ensure compliance with the general principles and agreed 
processes, ensure timely delivery, and act as lead authors 
on the ensuing publications.
Stage 2. Definition of the method and context of use(s) 
Identify which specific MRI biomarkers or MRI method 
will form the subject of the technical recommendations, 
and for which clinical questions they are to be used. The 
definition can be updated dynamically as the process 
develops, for instance if first results demonstrate that the 
original scope was too narrow, too wide, or too open for 
interpretation.
Stage 3. Review of literature Perform a detailed review of 
recent literature to identify key issues and inform the con-
tent of the first round of surveys. Extract technical param-
eters, tabulate and compare them to identify key areas 
of disagreement. Contact authors for missing technical 
specification. If relevant, compare reported biomarker 
values against technical parameters across the literature 
to identify the limiting factors.
Stage 4. Review of technical protocols Contact panel 
members and authors of recent literature with a request to 
share study protocols (including patient preparation and 
image processing) and vendor-specific MRI acquisition 
protocols. Review and compare these protocols to identify 
differences in parameters that have not been reported and 
gain a better understanding of more intricate differences 
between vendors, scanner models and software versions. 
This could include a review of data on different MR sys-
tems using reference objects or phantoms.
Stage 5. Delphi consensus formation Generate consensus 
statements using an approximation to the two-step modi-
fied Delphi method [17] to ensure all opinions are heard 
free from peer pressure.
The Delphi method is very well suited to reduce the bias 
caused by dominant personalities influencing the opinion 
of the group. It is an iterative method that determines 
reliable consensus in practice guidelines on health-care-
related issues [20, 21] and on topics where there is little 
or no definitive evidence and where opinion important 
[22]. At each iteration, participants are invited to respond 
to a survey that will also include an anonymous summary 
of the previous responses. Discussion in a face-to-face 
meeting between all respondents usually follows one or 
several of the rounds.
In the approximate Delphi method adopted by 
PARENCHIMA, consensus on a topic is pre-defined as at 
least 75% agreement. At least two rounds of surveys must 
be completed. Statements may be rephrased after each 
iteration, and additional respondents can be recruited. 
The first survey has an open format where the panel 
defines questions that address the areas of disagreement 
identified in stage 3 and 4 in a format most appropriate 
to the question. Examples are multiple-choice questions 
for optimal values of a technical parameter, or a binary 
agree/disagree format for qualitative statements. The sur-
vey in subsequent rounds must have a simplified multiple-
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choice format with only three options: (1) “I agree”, (2) 
“I disagree”, (3) “I have insufficient experience to make a 
recommendation”. There must be an open comment box 
after each question to explain the choice that was made. 
Questions that reach consensus in a previous round will 
be closed for voting, but are summarised to the respond-
ents in the subsequent round, with an opportunity to com-
ment in a free-text field.
Consensus statements may refer to all different areas rel-
evant to an MRI biomarker: patient preparation, sequence 
details (acquisition), quantification model, data analysis 
and reporting. To interpret the results, the surveys should 
collect relevant data on the background of the responder 
(e.g. expertise, level of experience). For responders that 
work as a team or in close collaboration, each individual 
team member can submit a separate response to the sur-
veys provided they are answered independently and with-
out discussing the questions or answers. The chair and the 
co-chair of the expert panels can also submit responses. 
Survey respondents should be instructed to select the 
answer that reflects their personal opinion and not neces-
sarily their current practice (which may be limited due to 
available infrastructure).
A face-to-face meeting is held after the first round of sur-
veys with a representative cross section of panel mem-
bers. The purpose of this meeting is to refine and extend 
the surveys for future rounds and drive consensus on con-
tentious issues by careful consideration of the arguments.
Stage 6. Reporting of recommendations The recommen-
dations should be published in a peer-reviewed journal 
using vendor-neutral language and terminology. These 
should detail not only the recommendations themselves, 
but also the process and rationale underlying the choices 
that were made to help experts understand their scope 
and limitations.
Where possible, detailed vendor-specific implementations 
in compliance with the recommendations should be pub-
lished as supplementary material on a version-controlled 
open-access website. If the recommended approach is not 
available in particular scanner models or software ver-
sions, the panel may instead provide some guidance on 
how to set up acceptable alternative sequences.
For reporting of results, a “traffic light” system is pro-
posed to issue recommendations based on the degree of 
consensus achieved through the survey. A “green light” 
in a question indicates consensus (closed issues). An 
“orange light” indicates an open issue where responses 
show clear preferences and a consensus is within reach. 
A “red light” is an open issue where no clear recom-
mendation emerges and more info and data are needed. 
When calculating the percentage of responses, the abstain 
responses (i.e. “I have insufficient experience to make 
a recommendation”) will be excluded. However, the 
percentage of abstain responses for each item will be 
reported, to reflect the level of familiarity of the experts 
with the topic and to assess the current level of interest 
in the topic within the community.
The authorship on the publications reporting the recom-
mendations will be defined according to the ICMJE crite-
ria (International Committee of Medical Journal Editors). 
In particular, this means that authors have provided sub-
stantial contributions to the development of the recom-
mendation. Those who wish to express their support to 
the recommendations without having contributed sub-
stantially can be recognised as signatories in an acknowl-
edgement section. There are various ways that the panel 
members can contribute substantially to the process:
1. Contributing technical details of protocols or 
responses to surveys.
2. Helping to collect, tabulate and compare protocols 
and surveys submitted.
3. Helping to develop, organise and document the 
online supplementary material (GitHub or equiva-
lent).
4. Regularly taking part in teleconferences or discus-
sions of the panel to define a consensus.
5. Other substantial contributions to the conception or 
design of the work; or the acquisition, analysis, or 
interpretation of data for the work (specify).
6. Drafting the work.
7. Revising the work critically for important intellec-
tual content.
8. Final approval of the version to be published.
9. Agreement to be accountable for all aspects of the 
work in ensuring that questions related to the accu-
racy or integrity of any part of the work are appro-
priately investigated and resolved.
To qualify for authorship, a panel member will therefore 
need at least one contribution from 1 to 5 AND at least 
one contribution from 6 to 7 AND 8 AND 9. Author-
ship order will align to the following principles: first 
author: junior co-chair; last author: senior chair; “middle 
authors”: filled in the survey but no other contributions; 
“outer authors”: filled in the survey and helped organise 
the material (junior at the front, senior at the end).
Stage 7. Maintenance of the recommendations The panel 
will remain in existence, though its membership may 
evolve. At regular intervals or on an ad hoc basis, the 
panel will revisit the recommendations, review novel evi-
dence and formulate an upgrade if needed. An upgrade 
can consist of changing the traffic light of any given rec-
ommendation (e.g. orange to green), adding new consen-
sus statements or refining existing statements (e.g. nar-
rower range of parameters). Upgrades should be decided 
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by consensus in the same manner as the original recom-
mendations. The panel can also choose at any time to add 
submitted protocols to the open-access site [19] provided 
they are in line with the current version of the recom-
mendations.
Discussion
This paper reports a process designed to generate consen-
sus-based technical recommendations on measuring renal 
MRI biomarkers. The process has been developed in the 
context of renal MRI, but is not specific to this application 
area and could therefore be applied to other potential MRI 
biomarkers.
The process was developed iteratively and was shaped 
through the application to four renal MRI techniques with 
very different issues as far as consensus formation is con-
cerned: T1 and T2 contrast is widely used for morphological 
measures, but quantitative mapping for body applications 
(to assess fibrosis and oedema) remains to be established; 
BOLD is technically a very similar method (T2* relaxation 
time mapping), but because of the association with oxygena-
tion has developed into a distinct sub-speciality within renal 
MRI; DWI is an established technique but is very versatile 
and given enough acquisition time can probe a wide range of 
structural features such as renal fibrosis, cellular (inflamma-
tory or tumorous) infiltration or oedema; ASL is becoming 
well established in the brain for assessment of grey matter 
perfusion, but it is relatively novel in the kidney and product 
sequences for body ASL are still evolving and have not been 
settled by the vendors.
Despite these widely different methods, the process 
proved effective and generated 166 consensus statements 
in total, with 36 on T1 and T2 mapping (17 respondents), 
14 on BOLD (24 respondents), 57 on DWI (21 respond-
ents) and 59 on ASL (23 respondents). Combined, it can 
be expected that these will promote a significant alignment 
of the research in this area and form the foundation for an 
international reference standard in clinical renal MRI. These 
first recommendations should be seen as part of a dynamic 
process continuously moving towards ever-closer align-
ment when novel evidence or technologies emerge in the 
literature.
The areas where no consensus was possible are informa-
tive and serve to highlight key open issues that should be pri-
oritised in future research. An interesting example is patient 
preparation. In the Aarhus meeting, it was agreed that all 
panels would ask the same questions regarding the need to 
control diet, hydration status and salt intake before the scan, 
as the same patient preparation is useful for multiparametric 
studies. All panels reached consensus on hydration status, 
but only the BOLD panel had consensus on diet, and only 
the DWI panel had consensus on salt intake. The results 
illustrate that the effects on diet and salt intake on most 
renal MRI biomarkers are not well understood and should be 
investigated systematically, e.g. by comparing results with 
different preparation states in the same subjects.
To ensure wider acceptance by the field as a whole, it is 
critical that the consensus is built by a representative col-
lection of experts. Considering that renal MRI is currently 
a relatively small field of research, the process has proven 
effective in generating momentum and critical mass in the 
response (17–24 respondents per survey). The entire process 
from defining the scope of the panels until submission of 
the publications has taken approximately 1 year. This is a 
relatively fast turnaround time considering the scale of the 
initiative and the fact that the process itself had not yet been 
tried and tested.
Interestingly, we found that none of the vendor-specific 
protocols contributed by various sites in stage 4 of the pro-
cess were in full compliance with the recommendations 
made. This by itself provides strong evidence that the end 
result represents the view of the entire community rather 
than a small number of authoritative voices. The implication 
was that no detailed protocols in vendor-specific terminol-
ogy were able to be uploaded as supplementary material at 
this stage [19].
Sustainability and governance
A currently unresolved point of discussion is how to sus-
tain the initiative in the long term. Long-term maintenance 
is essential in the fast-moving field of MRI physics, but 
requires a stable, sustainable and well-resourced governance 
structure. The PARENCHIMA task force will continue to 
govern the recommendations until the end of the project 
(May 2021), but it is currently unclear how the programme 
will progress beyond that.
A good practice example in a related field is the RECIST 
[23] (Response Evaluation Criteria in Solid Tumours) Work-
ing Group funded and governed by the European Organisa-
tion for Research and Treatment of Cancer (EORTC). Its 
mission is “to ensure that RECIST undergoes continued test-
ing, validation and updating” [24]. The working group has 
created several updates and modifications since the stand-
ard was first introduced over a decade ago. Another poten-
tial model is the series of “Acute Stroke Imaging Research 
Roadmaps” [25, 26]. These appear to be maintained and 
updated in a more ad hoc manner by pairing short meetings 
of the group with other relevant meetings. The recommenda-
tions for ASL in the brain [16] are developed and maintained 
in a similar way. They were originally developed as part of 
another COST Action project (ASL in Dementia, BM1103) 
and through an ISMRM-sponsored workshop. Recently, the 
community organised a workshop to discuss the need for 
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upgrading, but ultimately decided against this as the field 
had not sufficiently evolved. Inspiration can also be drawn 
from the approach to managing expert recommendations on 
radiological reporting, such as the long-standing Reporting 
and Data Systems (RAD) maintained by the American Col-
lege of Radiology (ACR) [27].
For the PARENCHIMA recommendations, a number of 
avenues were explored, but require further investigation.
The subject matter falls under the remit of the Quanti-
tative Imaging Biomarkers Alliance (QIBA) of the Radio-
logical Society of North America (RSNA), but QIBA has 
adopted a different evidence-based approach to support 
the development and confirmation of profiles focused on 
specific biomarkers. This is opposed to the more general 
recommendations here, which focus on multiple contrast 
mechanisms and biomarkers within four renal MRI modali-
ties. Nevertheless, specific biomarkers that emerge from the 
PARENCHIMA process could potentially be advanced using 
the QIBA approach. Another consortium funded by the NIH, 
the Quantitative Imaging Network (QIN), supports develop-
ment of quantitative imaging tools for the particular appli-
cation of predicting tumour response to therapy, and also 
enshrines core values of standardisation, repeatability, and 
wide translation. Should the PARENCHIMA effort expand 
towards oncology (renal masses), some collaboration with 
QIN could be considered.
The governing committee of the Quantitative MR (QMR) 
study group of the ISMRM was approached, but it does not 
have a charter of sufficient longevity, nor the resources, to 
support the maintenance and update of recommendations. 
The creation of an imaging working group within the Euro-
pean Renal Association was explored with the ERA-EDTA 
leadership but this did not align well with their organisation 
around clinical areas. Creating a separate society on renal 
MRI is a theoretical possibility and the experience of the 
SCMR (Society of Cardiovascular Magnetic Resonance) has 
demonstrated that this can be an effective vehicle for devel-
opment and maintenance of expert recommendations. How-
ever, it is doubtful whether the renal MRI field currently has 
sufficient critical mass to move in that direction. A poten-
tial intermediate avenue may be the creation of an ISMRM 
study group on renal MRI and including maintenance of the 
recommendations in its mission statement. Potentially, this 
could be embedded in a broader initiative by the ISMRM to 
develop and maintain recommendations for MRI data acqui-
sition and analysis across application domains.
Future developments
Apart from maintenance of the current recommenda-
tions, there is a need to develop consensus in other renal 
MRI biomarkers. Examples of relatively mature areas that 
would benefit from recommendations are renal dynamic 
contrast-enhanced MRI or MRI renography [28–34], phase-
contrast MRI of the renal arteries [35–38], or MRI volu-
metry [39–42]. Emerging methods such as magnetisation 
transfer imaging [43, 44], renal MR elastography [45–48], 
renal MRI spectroscopy [49, 50], positron emission tomog-
raphy (PET)/MRI [51], chemical exchange saturation trans-
fer (CEST) [52], 7T renal MRI [53], 23Na MRI [54] and 
hyperpolarised [1-13C]pyruvate MRI [55] and 129Xe MRI 
could also be potential candidates for recommendations. 
Other perspectives that could be taken in future work include 
the development of recommendations for biomarker panels 
where different complementary multiparametric sequences 
are run in the same study, or dedicated recommendations 
for cross-cutting issues such as region of interest (ROI) 
definition.
If sufficient capacity can be found, it would be useful 
to expand the remit of the expert panels to also include 
field testing of the recommendation. This will involve the 
supervision and subsequent evaluation of the recommended 
protocols and collect reporting bias and repeatability coef-
ficients from participating sites. This, in combination with a 
meta-analysis, can help estimate statistical power for future 
clinical research studies by interested stakeholders (e.g. new 
sites or pharmaceutical companies).
A second role that could be added to the remit of the 
panels, or else be realised through separate programmes [6], 
is to collect and provide reference data that can help qualify 
local implementations of the recommended methods. This 
can include example data on phantoms or healthy volunteer 
scans of different body compositions with repeatability data. 
These can then be used as benchmarks to verify implemen-
tations in new sites and check for artefacts caused by, for 
instance, hardware issues, field inhomogeneity, or imperfect 
shimming.
These roles can build on lessons learnt in neuroimaging, 
where reproducibility is a very active field of research and a 
number of best practices for data analysis and data sharing 
have been recommended recently [56]. Notably, the widely 
used and simple standard for data organisation “Brain Imag-
ing Data Structure (BIDS) [57]”, makes it much easier to 
share data, process data and re-run analyses automatically. 
The BIDS standard could be adapted to other application 
areas with few modifications.
Conclusion
The PARENCHIMA process for developing technical rec-
ommendations in renal MRI has been developed, reshaped 
and optimised to achieve a successful application to five 
very different MRI techniques (ASL, DWI, BOLD, T1 and 
T2). The process is fit for the purpose, having produced 166 
recommendations that are widely supported and are likely 
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to promote a more harmonised approach to renal MRI bio-
marker measurement. In the longer term, we expect this will 
lead to data that are more directly comparable between sites, 
scale up the evidence level for clinical utility, and lower the 
barriers to integrating MRI biomarkers in clinical research.
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